SPY332.03+1.97 0.60%
DIA272.04+3.63 1.35%
IXIC10,998.40+57.23 0.52%

Atossa Therapeutics Highlights Findings From Expanded Access Treatment With Endoxifen: 'Patient has taken Atossa's Endoxifen for 18 months without side effects and without cancer recurrence'

Benzinga · -